Celldex Therapeutics, Inc.
CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receā¦ read more
Healthcare
Biotechnology
39 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$22.90
Price-1.55%
-$0.36
1Y
Price
Market Cap
$1.521b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-8627.9%
EBITDA Margin-7753.4%
Net Profit Margin-6127.8%
Free Cash Flow MarginRevenue
$5.791m
-17.5%
1y CAGR+58.8%
3y CAGR+31.8%
5y CAGREarnings
-$199.609m
-26.4%
1y CAGR-21.3%
3y CAGR-30.8%
5y CAGREPS
-$3.01
-22.9%
1y CAGR-9.5%
3y CAGR-18.7%
5y CAGRBook Value
$655.406m
$692.407m
Assets$37.001m
Liabilities$3.031m
DebtDebt to Assets
0.4%
-
Debt to EBITDAFree Cash Flow
-$187.056m
-17.1%
1y CAGR-22.3%
3y CAGR-34.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company